Eli Lilly Announces Tirzepatide Cuts Diabetes Risk by 94% in Three-Year Study

Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.